October 7, 2026
Kymathera
Kymathera is advancing K-1728, an oral pan-mutant selective PI3Kα inhibitor, with its recent funding.
- Round
- Series B
- Amount raised
- $80M
- Lead investor
- —
- Industry
- Biotechnology, Pharmaceuticals
- Headquarters
- United States
- Employees
- 2-10 employees
- Website
- kymathera.com
- View profile →